Beta thalassemia major is a severe inherited hemoglobin disorder. Without ongoing treatment, patients cannot maintain adequate hemoglobin levels. Management requires a structured, evidence-based strategy that addresses both the immediate need for red cell support and the long-term consequences of treatment itself.

Treatment Approach

The cornerstone of management is a regular transfusion programme using specifically selected red cell products. This is combined with iron chelation therapy to manage the iron burden that inevitably accumulates with repeated transfusions.

The complete protocol specifies product selection criteria, compatible antigen matching, transfusion scheduling, and the full chelation strategy — see the full regimen below.

Clinical Targets

Pretransfusion hemoglobin maintained at 9.5–10.5 g/dL
Post-transfusion hemoglobin kept below 13–15 g/dL

References

Use leukodepleted packed red cells.
Use washed red cells for patients who have severe allergic reactions (Grade C, Class IIa).
Transfuse every 2–5 weeks, targeting a pretransfusion hemoglobin of 9.5–10.5 g/dL (Grade C, Class I).
Keep the post‑transfusion hemoglobin below 13–15 g/dL (Grade C, Class IIa).
Chelation therapy at the correct doses and frequency can balance iron excretion with iron accumulation from transfusions (Grade A, Class I).

DOI: 10.1002/hem3.70095

View source ↗

What Is the Treatment of Beta Thalassemia Major?

Treatment Approach

Clinical Targets

References